Loading
Tarsus Pharmaceuticals, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 19 Dec 2023.
Tarsus Pharmaceuticals, Inc.: what insiders have been doing
Every trade that managers of Tarsus Pharmaceuticals, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. In the past year (18 October 2025 to 18 October 2026), 57 filings came from 19 insiders.
All open-market trades in the period are sales: 30 sales worth €8.5M, by 8 insiders, with no purchase on record. The amount is not disclosed for 2 filings. At €792k, the sale published on 17 September 2026 by Link William J Phd is the largest of the period (0.026% of market cap).
For context, the typical company on the same exchange (median of 5,810 companies) published 19 filings over the same period, against 57 filings here. Since 2021, the database holds 4 purchases and 133 sales by insiders of the company. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 451.4 m USD and net income at -66.4 m USD.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Cytosorbents Corp. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
224
Thresholds
n/a
Buy Volume
€2M
4 ops. · all time
Sell Volume
€33M
133 ops. · all time
Who traded when
BuySaleBobak R. Azamian12 sales
Elizabeth Yeu Lin8 sales
William J. Phd Link6 sales
Neervannan Seshadri5 sales
Whitfield Dianne C.4 sales
Mottiwala Aziz3 sales
+2 other insiders
Since the insiders bought
- +159.9%Entry US$20.01 · Close at T+365 US$52.00
- +54.8%Entry US$17.12 · Close at T+365 US$26.51
- +33.5%Entry US$12.51 · Close at T+365 US$16.70
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Tarsus Pharmaceuticals, Inc. Strong Buy (bullish), based on 10 analysts. Average price target: US$99.80.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 17,896 of 24,148 companies
35.3
score / 100
Value30
Quality41
FCF yld-0.7%
Earn yld-2.1%
EV/EBITDA·
ROE-14%
Gross mgn93%
Net mgn-15%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$72.29
Analyst consensus
10 analystsStrong buy
US$84.00Target US$99.80(+38%)US$116.00
Income statement
RevenueUS$451.4M
Gross profitUS$420.7M93% margin
EBITDA-US$54.2M-12% margin
Net income-US$66.4M-7.7% margin
Valuation
PER (forward)-262.9x
P/Book9.0x
Beta0.45
Balance sheet & cash
Market capUS$3.4B
Total debtUS$72.4M
Free Cash Flow-US$22.3M
Debt / Equity26%
Profitability & ownership
ROE-13.7%
ROA-5.5%
% insiders2.7%
% institutions100.0%
Last declaration on 17 September 2026
Declarations224 total
201 sharesCommon StockSEC:0001228684-26-000010:0
759 shares@ US$79.000.0017% mcap1.9% of flowCommon StockSEC:0001228684-26-000010:2
66 shares@ US$80.010.0001% mcap0.2% of flowCommon StockSEC:0001228684-26-000010:3
302 sharesCommon StockSEC:0001181186-26-000008:0
11,675 shares@ US$78.330.026% mcap29.1% of flowCommon StockSEC:0001228684-26-000010:1
201 sharesCommon StockSEC:0001051578-26-000010:0
12,500 shares@ US$78.37960.028% mcap100.0% of flowCOMMONSEC144:0001628280-26-062078
2,900 shares@ US$91.270.0075% mcap3.0% of flowCommon StockSEC:0001827672-26-000013:1
5,387 shares@ US$85.000.013% mcap12.2% of flowCommon StockSEC:0001842190-26-000011:0
7,100 shares@ US$90.270.018% mcap7.2% of flowCommon StockSEC:0001827672-26-000013:0
5,386 shares@ US$90.000.014% mcap12.9% of flowCommon StockSEC:0001842190-26-000011:1
1,590 shares@ US$85.000.0038% mcap3.6% of flowCommon StockSEC:0001842190-26-000011:2
1,590 shares@ US$90.000.0040% mcap3.8% of flowCommon StockSEC:0001842190-26-000011:3
10,000 shares@ US$90.55870.026% mcap59.3% of flowCOMMONSEC144:0001628280-26-060766
10,773 shares@ US$87.49980.027% mcap25.1% of flowCommonSEC144:0001959173-26-006758
3,180 shares@ US$87.500.0078% mcap7.4% of flowCommonSEC144:0001959173-26-006760
4,564 shares@ US$85.000.011% mcap24.4% of flowCommonSEC144:0001959173-26-006753
10,000 shares@ US$80.060.023% mcap9.0% of flowCommon StockSEC:0001827672-26-000011:0
5,387 shares@ US$80.000.012% mcap11.5% of flowCommon StockSEC:0001842190-26-000009:1
1,590 shares@ US$80.000.0036% mcap3.4% of flowCommon StockSEC:0001842190-26-000009:2
4,601 shares@ US$73.860.0096% mcap9.0% of flowCommon StockSEC:0001842190-26-000009:0
81,332 shares@ US$71.85220.16% mcap50.8% of flowCommonSEC144:0001959173-26-006443
53,043 shares@ US$72.000.11% mcap33.4% of flowCommonSEC144:0001959173-26-006221
4,582 sharesCommon StockSEC:0001827672-26-000009:0
5,418 sharesCommon StockSEC:0001827672-26-000009:1
25 of 224 declarations
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. (ticker: TARS) is a U.S.-listed biopharmaceutical company trading on the NASDAQ market in the United States, with headquarters in Irvine, California. Founded in November 2016, the company was built around a focused strategy in ophthalmology and infectious-disease adjacent therapeutics, aiming to identify and commercialize differentiated products in underserved, high-unmet-need markets. For international investors, Tarsus is best viewed as a specialty-healthcare growth story rather than a diversified large-cap pharmaceutical group.
The company’s core value driver is XDEMVY® (lotilaner ophthalmic solution) 0.25%, which received FDA approval in the United States in July 2023 for the treatment of Demodex blepharitis and was launched commercially in August 2023. That approval marked a major inflection point, shifting Tarsus from a development-stage biotech into a commercial-stage company focused on market education, patient access, payer coverage, and adoption among eye-care professionals. In practical terms, the company’s operating model now revolves around building awareness of the disease, driving prescriptions, and scaling a specialized ophthalmology sales effort across the U.S.
Read moreShow less
From a competitive standpoint, Tarsus holds an important first-mover position in Demodex blepharitis, a condition that has historically been underdiagnosed and under-treated. This gives the company a meaningful commercial opportunity if it can continue converting awareness into sustained prescription demand. At the same time, the business remains concentrated in a single lead asset, which means execution risk, reimbursement dynamics, and the pace of physician adoption are all critical variables for investors to monitor.
Beyond the U.S. franchise, Tarsus has an international dimension through licensing and development partnerships. Its China-related regulatory pathway, advanced with partner Grand Pharmaceutical Group, provides an additional option for value creation outside the domestic market. The company has also signaled pipeline ambitions beyond XDEMVY, including work on a potential oral prophylactic approach for Lyme disease prevention, suggesting a broader long-term platform strategy.
Recent business highlights reinforce the commercial momentum. In 2026, Tarsus reported continued growth and reaffirmed its full-year 2026 guidance for XDEMVY net product sales of $670–700 million, while also stating a peak sales potential above $2 billion. It has also continued to expand its commercial footprint and investor messaging around deeper penetration in eye-care practices. Overall, TARS is a U.S. NASDAQ-listed specialty pharma company with a compelling single-product launch story, a clear U.S. commercial focus, and emerging pipeline and international upside that could broaden the investment case over time.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
